ReviewCurrent opinion in pharmacology2017
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.
Review in Current opinion in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.Systematic reviews · 2024Pooled it
- Metabolism-Driven Modulation by the Human Microbiota: Implications for Cancer Therapy and Emerging Strategies.Advances in experimental medicine and biology · 2026Review
- Interactions of bile acids and gut microbiota modulate neurological health: a comprehensive review on mechanisms and therapeutic potential of dietary phytochemicals.Frontiers in microbiology · 2026Review
- Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases.Seminars in liver disease · 2025Review
- Multifaceted Interactions Between Bile Acids, Their Receptors, and MASH: From Molecular Mechanisms to Clinical Therapeutics.Molecules (Basel, Switzerland) · 2025Review
- The gut microbiome and cancer: from tumorigenesis to therapy.Nature metabolism · 2025Review
- Engineered FGF19BMC biotechnology · 2023Article
- Multi‑omics‑based analysis of the regulatory mechanism of gypenosides on bile acids in hypercholesterolemic mice.Experimental and therapeutic medicine · 2023Article
- Bile acid-mediated signaling in cholestatic liver diseases.Cell & bioscience · 2023Review
- The Gut Microbiome and Ferroptosis in MAFLD.Journal of clinical and translational hepatology · 2023Review
- Influence of high-fat diet on host animal health via bile acid metabolism and benefits of oral-fed Streptococcus thermophilus MN-ZLW-002.Experimental animals · 2022Article
- Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease.Nature reviews. Nephrology · 2022Review
- Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet.Frontiers in pharmacology · 2022Article
- Functional and Phylogenetic Diversity of BSH and PVA Enzymes.Microorganisms · 2021Review
- Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease.American journal of translational research · 2021Article
- Therapeutic Opportunities of GPBAR1 in Cholestatic Diseases.Frontiers in pharmacology · 2021Review
- Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency.Laboratory investigation; a journal of technical methods and pathology · 2020Article
- Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?Physiology (Bethesda, Md.) · 2020Review
- Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells.Life science alliance · 2020Article
- Leveraging the Gut to Treat Metabolic Disease.Cell metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Bile acids are central signals in enterohepatic communication and also integrate microbiota-derived signals into this signaling axis. Discovery of the tissue distribution and signaling pathways activated by the natural receptors for bile acids, farnesoid X receptor and G protein-coupled bile acid receptor 1 (GPBAR1) also known as TGR5, and bile acid transporters has led to the development of therapeutic agents that target these molecules. Obeticholic acid, a selective FXR agonist, and NGM282, a non-mitogenic FGF-19 analog, are two of the agents in this pipeline. Obeticholic acid has been approved by regulatory agencies for use in patients with primary biliary cholangitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.